TY - JOUR
T1 - Case Report
T2 - QT Prolongation and Abortive Sudden Death Observed in an 85-Year-Old Female Patient With Advanced Lung Cancer Treated With Tyrosine Kinase Inhibitor Osimertinib
AU - Kondo, Moë
AU - Kisanuki, Megumi
AU - Kokawa, Yosuke
AU - Gohara, Seiichiro
AU - Kawano, Osamu
AU - Kagiyama, Shuntaro
AU - Maruyama, Toru
AU - Odashiro, Keita
AU - Maehara, Yoshihiko
N1 - Publisher Copyright:
© Copyright © 2021 Kondo, Kisanuki, Kokawa, Gohara, Kawano, Kagiyama, Maruyama, Odashiro and Maehara.
PY - 2021/3/19
Y1 - 2021/3/19
N2 - Cardiac arrest occurred in an 85-year-old female administered osimertinib for advanced lung cancer expressing epidermal growth factor receptor (EGFR) mutations. Electrocardiogram (ECG) recorded at recurrence of spontaneous circulation showed sinus rhythm associated with mild QT prolongation (QTc = 455 ms) to which silent myocardial ischemia and coadministration of itraconazole and herbal drug causing hypokalemia (2.1 mEq/L) may have contributed. Discontinuation of osimertinib, itraconazole and herbal drug, potassium supplementation and percutaneous coronary intervention alleviated QT prolongation (QTc = 432 ms). Osimertinib is the third-generation tyrosine kinase inhibitor lengthening QT interval, and careful monitoring of ECG, serum potassium and drugs coadministered during chemotherapy including osimertinib are highly required.
AB - Cardiac arrest occurred in an 85-year-old female administered osimertinib for advanced lung cancer expressing epidermal growth factor receptor (EGFR) mutations. Electrocardiogram (ECG) recorded at recurrence of spontaneous circulation showed sinus rhythm associated with mild QT prolongation (QTc = 455 ms) to which silent myocardial ischemia and coadministration of itraconazole and herbal drug causing hypokalemia (2.1 mEq/L) may have contributed. Discontinuation of osimertinib, itraconazole and herbal drug, potassium supplementation and percutaneous coronary intervention alleviated QT prolongation (QTc = 432 ms). Osimertinib is the third-generation tyrosine kinase inhibitor lengthening QT interval, and careful monitoring of ECG, serum potassium and drugs coadministered during chemotherapy including osimertinib are highly required.
UR - http://www.scopus.com/inward/record.url?scp=85105990197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105990197&partnerID=8YFLogxK
U2 - 10.3389/fcvm.2021.655808
DO - 10.3389/fcvm.2021.655808
M3 - Article
AN - SCOPUS:85105990197
VL - 8
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
SN - 2297-055X
M1 - 655808
ER -